Crucell of the Netherlands and Vaxin, a Birmingham, Alabama, USA-basedcompany, have signed an agreement to jointly develop new types of vaccines that will be suitable to be administered to patients in a non-invasive way. The companies said that their aim is to produce vaccines "which make injections obsolete."
The project will combine Crucell's PER.C6 cell line and related vaccination technology with Vaxin's skin delivery system for vaccines, known as EasyVax. This enables the development of new antiviral vaccines that can be administered non-invasively to the surface of the skin using a patch, the firms said, adding that this vaccination system "eliminates pain and potential contamination."
Crucell and Vaxin will develop two antiviral vaccines and will share costs and profits. One of the diseases targeted for vaccination development is rabies, which kills 60,000-80,000 people in Asia each year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze